IDD Fundamental Analysis - INNATE PHARMA SA

Fundamental Rating

IDD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. IDD has a bad profitability rating. Also its financial health evaluation is rather negative. IDD is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IDD has reported negative net income.

In the past year IDD has reported a negative cash flow from operations.

In the past 5 years IDD always reported negative net income.

In the past 5 years IDD always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -49.55%, IDD is doing worse than 65.06% of the companies in the same industry.

With a Return On Equity value of -895.24%, IDD is not doing good in the industry: 69.88% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROIC	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 49.52%, IDD perfoms like the industry average, outperforming 46.99% of the companies in the same industry.

IDD's Gross Margin has declined in the last couple of years.

IDD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IDD does not have a ROIC to compare to the WACC, probably because it is not profitable.

IDD has more shares outstanding than it did 1 year ago.

IDD has more shares outstanding than it did 5 years ago.

The debt/assets ratio for IDD is higher compared to a year ago.

2.2 Solvency

IDD has an Altman-Z score of -6.31. This is a bad value and indicates that IDD is not financially healthy and even has some risk of bankruptcy.

IDD's Altman-Z score of -6.31 is on the low side compared to the rest of the industry. IDD is outperformed by 72.29% of its industry peers.

A Debt/Equity ratio of 11.55 is on the high side and indicates that IDD has dependencies on debt financing.

Looking at the Debt to Equity ratio, with a value of 11.55, IDD is doing worse than 69.88% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Altman-Z	-6.31

ROIC/WACCN/A

WACC6.48%

2.3 Liquidity

A Current Ratio of 2.21 indicates that IDD has no problem at all paying its short term obligations.

With a Current ratio value of 2.21, IDD perfoms like the industry average, outperforming 45.78% of the companies in the same industry.

IDD has a Quick Ratio of 2.21. This indicates that IDD is financially healthy and has no problem in meeting its short term obligations.

IDD has a Quick ratio (2.21) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.21
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IDD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.

The Revenue for IDD has decreased by -75.86% in the past year. This is quite bad

Measured over the past years, IDD shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

3.2 Future

Based on estimates for the next years, IDD will show a decrease in Earnings Per Share. The EPS will decrease by -3.32% on average per year.

IDD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.06% yearly.

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.32%

EPS Next 5YN/A

Revenue Next Year-26.21%

Revenue Next 2Y3.05%

Revenue Next 3Y2.41%

Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IDD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IDD. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

IDD's earnings are expected to decrease with -3.32% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.27%

EPS Next 3Y-3.32%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IDD!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INNATE PHARMA SA

FRA:IDD (12/8/2025, 7:00:00 PM)

1.654

-0.08 (-4.5%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-13 2025-11-13/bmo

Earnings (Next)N/A N/A

Inst Owners10.45%

Inst Owner ChangeN/A

Ins Owners0.92%

Ins Owner ChangeN/A

Market Cap152.44M

Revenue(TTM)6.00M

Net Income(TTM)-46.05M

Analysts80

Price Target5.58 (237.36%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	25.41
P/FCF	N/A
P/OCF	N/A
P/B	29.64
P/tB	29.64
EV/EBITDA	N/A

EPS(TTM)-0.55

EYN/A

EPS(NY)-0.5

Fwd EYN/A

FCF(TTM)-0.45

FCFYN/A

OCF(TTM)-0.45

OCFYN/A

SpS0.07

BVpS0.06

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	49.52%
FCFM	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.84%
Cap/Sales	2.82%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.21
Quick Ratio	2.21
Altman-Z	-6.31

F-Score1

WACC6.48%

ROIC/WACCN/A

Cap/Depr(3y)22.77%

Cap/Depr(5y)23.45%

Cap/Sales(3y)3.3%

Cap/Sales(5y)8.22%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.32%

EPS Next 5YN/A

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

Revenue Next Year-26.21%

Revenue Next 2Y3.05%

Revenue Next 3Y2.41%

Revenue Next 5Y43.06%

EBIT growth 1Y-31.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year68.86%

EBIT Next 3Y68.81%

EBIT Next 5YN/A

FCF growth 1Y-25.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-29.1%

OCF growth 3YN/A

OCF growth 5YN/A

INNATE PHARMA SA / IDD.DE FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 1 / 10 to IDD.DE.

What is the valuation status of INNATE PHARMA SA (IDD.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IDD.DE). This can be considered as Overvalued.

Can you provide the profitability details for INNATE PHARMA SA?

INNATE PHARMA SA (IDD.DE) has a profitability rating of 0 / 10.

Can you provide the expected EPS growth for IDD stock?

The Earnings per Share (EPS) of INNATE PHARMA SA (IDD.DE) is expected to decline by -32.84% in the next year.

INNATE PHARMA SA (IDD.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INNATE PHARMA SA / IDD.DE FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

What is the valuation status of INNATE PHARMA SA (IDD.DE) stock?

Can you provide the profitability details for INNATE PHARMA SA?

Can you provide the expected EPS growth for IDD stock?